psalexa
logo

Myocarditis Therapeutics Pipeline Analysis

Myocarditis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11284
Available Format:

Myocarditis is an inflammatory disorder of cardiac muscles that is caused by toxic substances, immune system, infections and autoimmune disease. The infectious strains (bacteria or viruses) are generally responsible for the acute myocarditis in which subsequent disturbance of right or left ventricular function occurs. Myocarditis can be easily diagnosed by long-term electrocardiogram, computed tomography, magnetic resonance imaging, electrocardiography, and diagnostic catheterization. Myocarditis can be symptomatized by fatigue or listlessness, joint pain, leg swelling, rapid breathing, chest pain, rapid heart rate, fainting, and low urine output. Vycellix, Inc. is in the process of developing VY-OZ as an adjuvant therapy for dampening viral inflammation, for the treatment of myocarditis. Targeted Cell Therapies, LLC is also in the process of developing a drug candidate targeting monocyte chemoattractant protein-1 (MCP-1/CCL2), for the treatment of myocarditis. Some of the companies and universities having the pipeline of myocarditis include Targeted Cell Therapies, LLC, Vycellix, Inc., Stanford University, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry